The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differentiating bladder cancer (BLCA) tumor immune microenvironment (TME) profiles based on predicted intrinsic radiosensitivity (RS).
 
Winston Vuong
No Relationships to Disclose
 
Shinjini Ganguly
No Relationships to Disclose
 
Aysegul Balyimez
No Relationships to Disclose
 
Ahmed Halima
No Relationships to Disclose
 
Cassandra Kerr
No Relationships to Disclose
 
Mark L. Day
No Relationships to Disclose
 
Scott A. Tomlins
Employment - Strata Oncology
Leadership - Strata Oncology
Stock and Other Ownership Interests - Javelin Oncology; Strata Oncology
Consulting or Advisory Role - Astellas Medivation
Research Funding - Astellas Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent issued to Strata Oncology related to MSI determination and checkpoint inhibitor benefit. (Inst); I am a co-inventor on a patent issued to the University of Michigan on ETS gene fusions in prostate and am included in the royalty stream. The diagnostic field of use was licensed to Hologic/Gen-Probe (who sublicensed some rights to Ventana/Roche) and is; I am a co-inventor on a provisional patent filed by Strata Oncology on the Immunotherapy Response Score biomarker. (Inst)
Travel, Accommodations, Expenses - Strata Oncology
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Timothy An-thy Chan
Leadership - Bristol-Myers Squibb; Cancer Genetics; Illumina
Stock and Other Ownership Interests - Gritstone Bio
Honoraria - Illumina
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Illumina; LG Chem; Pfizer
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Nysnobio (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigen discovery and genomic biomarkers for immunotherapy response
 
Babal Jha
No Relationships to Disclose
 
Omar Y. Mian
Consulting or Advisory Role - Bayer
Research Funding - Gilead Sciences (Inst); Varian Medical Systems (Inst)
(OPTIONAL) Uncompensated Relationships - Veracyte